MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Johnson and Johnson

Fechado

SetorSaúde

160.12 3.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

155.34

Máximo

160.62

Indicadores-chave

By Trading Economics

Rendimento

3.4B

Vendas

20M

23B

P/E

Médio do Setor

28.643

63.778

EPS

2.04

Rendimento de Dividendos

2.99

Margem de lucro

15.235

Funcionários

138,100

EBITDA

652M

5.9B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.41% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.99%

2.39%

Próximos Ganhos

15 de abr. de 2025

Próxima data de ex-dividendo

19 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

32B

400B

Abertura anterior

157.08

Fecho anterior

160.12

Sentimento de Notícias

By Acuity

62%

38%

339 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Johnson and Johnson Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mar. de 2025, 15:16 UTC

Grandes Movimentos do Mercado

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 de mar. de 2025, 13:59 UTC

Grandes Movimentos do Mercado

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2 de abr. de 2025, 12:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson Expects 2026 Earnings Dilution to Be Reduced to About 21c/Shr

2 de abr. de 2025, 12:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson Expects Deal to Dilute Adj EPS by About 25c in 2025 >JNJ

2 de abr. de 2025, 12:48 UTC

Aquisições, Fusões, Aquisições de Empresas

J&J: Deal Expected to Accelerate 2025 Sales Growth by About 0.8% With About $700M in Incremental Sales >JNJ

2 de abr. de 2025, 12:45 UTC

Aquisições, Fusões, Aquisições de Empresas

J&J: Addition of CAPLYTA Strengthens Lineup of Therapies With $5 Billion+ Potential in Peak Yr Sales >JNJ

2 de abr. de 2025, 12:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson: sNDA Submitted to FDA for CAPLYTA as Adjunctive Treatment for Major Depressive Disorder >JNJ

2 de abr. de 2025, 12:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

1 de abr. de 2025, 20:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 de abr. de 2025, 16:09 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, Southwest, Delta, MicroStrategy, PVH, Newsmax, and More -- Barrons.com

1 de abr. de 2025, 13:51 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, PVH, Southwest, Newsmax, and More -- Barrons.com

1 de abr. de 2025, 12:15 UTC

Principais Notícias

Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected -- Barrons.com

1 de abr. de 2025, 11:37 UTC

Conversa de Mercado

Johnson & Johnson To Reverse $7 Billion of Talc Reserve -- Market Talk

1 de abr. de 2025, 10:36 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, XPeng, PVH, Progress Software, J&J, Newsmax, Southwest, and More -- Barrons.com

1 de abr. de 2025, 01:04 UTC

Principais Notícias

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

21 de mar. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 de mar. de 2025, 13:35 UTC

Ganhos
Ações em Alta

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 de mar. de 2025, 01:00 UTC

Principais Notícias

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 de fev. de 2025, 22:22 UTC

Principais Notícias

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 de fev. de 2025, 13:00 UTC

Principais Notícias

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 de jan. de 2025, 07:00 UTC

Principais Notícias

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 de jan. de 2025, 21:39 UTC

Ganhos

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 de jan. de 2025, 19:41 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 de jan. de 2025, 17:38 UTC

Conversa de Mercado
Ganhos

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 de jan. de 2025, 16:48 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 de jan. de 2025, 14:51 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 de jan. de 2025, 14:09 UTC

Principais Notícias
Ganhos

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 de jan. de 2025, 13:04 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 de jan. de 2025, 12:47 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Johnson and Johnson Previsão

Preço-alvo

By TipRanks

8.41% parte superior

Previsão para 12 meses

Média 168.42 USD  8.41%

Máximo 185 USD

Mínimo 152 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Johnson and Johnson - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

6

Comprar

8

Manter

0

Vender

Pontuação Técnica

By Trading Central

153.13 / 164.36Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

339 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.